Loading
Cevostamab is an experimental investigational agent whose form is not stated in the registry from Hoffmann-La Roche in phase 3 trials for multiple myeloma, with its target not yet stated publicly.
Cevostamab is an investigational agent whose form is not stated in the registry developed by Hoffmann-La Roche. The sponsor describes its target as FcRH5, which OnCo does not yet have a target page for. ClinicalTrials.gov describes the intervention as: Participants will receive cevostamab IV as per the schedule given in the protocol. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07555938 (Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma), in multiple myeloma. The largest, NCT07555938, plans to enrol 380 participants with primary completion expected 2028-10-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.Cevostamab binds its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Cevostamab" OR ABSTRACT:"Cevostamab") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Cevostamab, not a curated reading list.
Shares Roche / Genentech, Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Roche / Genentech and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Roche / Genentech and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.